Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reimbursement In Brief

This article was originally published in The Gray Sheet

Executive Summary

CMS opens national coverage analysis for PET tracers to diagnose dementia. HHS Office of Inspector General reports on prosthetics and orthotics payments. More reimbursement news.

You may also be interested in...



Imaging Groups Oppose CMS Coverage Proposal For Beta-Amyloid PET

Medical imaging manufacturers and professional societies echoed Eli Lilly’s criticism of the CMS proposal to cover beta-amyloid PET for use in patients suffering from dementia and neurodegenerative disease.

HHS OIG Expects Almost $4 Billion In Recoveries From First Half Of Fiscal 2013

Its spring 2013 Semiannual Report to Congress says the Office of Inspector General expects recoveries of about $3.8 billion from audits and investigations undertaken in the first half of fiscal year 2013, among other findings.

CMS Urged To Cover Beta Amyloid PET Scans For Alzheimer's, But Cautiously

Imaging stakeholders call for Medicare coverage of beta amyloid positron emission tomography scans to help diagnose and manage dementia patients, but clinical societies warn against using the technology as a screening tool for Alzheimer’s disease. CMS took comments through Nov. 8 on its ongoing national coverage analysis.

Related Content

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031657

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel